Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) is one of 82 public companies in the “Technology Hardware, Storage & Peripherals” industry, but how does it weigh in compared to its competitors? We will compare Mymd Pharmaceuticals to related companies based on the strength of its earnings, profitability, institutional ownership, analyst recommendations, valuation, risk and dividends.
Valuation & Earnings
This table compares Mymd Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Mymd Pharmaceuticals | N/A | -$11.63 million | -0.14 |
| Mymd Pharmaceuticals Competitors | $23.46 billion | $3.24 billion | 17.21 |
Mymd Pharmaceuticals’ competitors have higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Institutional & Insider Ownership
9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.3% of shares of all “Technology Hardware, Storage & Peripherals” companies are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of shares of all “Technology Hardware, Storage & Peripherals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Mymd Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mymd Pharmaceuticals | N/A | -76.40% | -35.10% |
| Mymd Pharmaceuticals Competitors | -609.25% | -15.44% | 3.05% |
Analyst Ratings
This is a summary of recent ratings for Mymd Pharmaceuticals and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mymd Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Mymd Pharmaceuticals Competitors | 1051 | 4266 | 7598 | 358 | 2.55 |
As a group, “Technology Hardware, Storage & Peripherals” companies have a potential upside of 25.83%. Given Mymd Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Mymd Pharmaceuticals has less favorable growth aspects than its competitors.
Summary
Mymd Pharmaceuticals competitors beat Mymd Pharmaceuticals on 11 of the 13 factors compared.
Mymd Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Mymd Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymd Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
